A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

NCT02156804 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1009

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Nivolumab (BMS-936558)

Sponsor

Bristol-Myers Squibb